CD19-targeted immunotherapy has significantly improved the treatment options for various B-cell malignancies, spanning aggressive Diffuse Large B-cell Lymphoma (DLBCL) to the more indolent Waldenström Macroglobulinemia (WM). The gene discussed is CD19; the disease is Waldenstrom macroglobulinemia.